Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.41 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | ALB | P02768 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411743 | 0.79 | ERN1 (0.58) | ERN1 | |
| SCHEMBL412862 | 0.79 | TTR (0.64) | ERN1TTRALBMEN1KMT2A | |
| SCHEMBL28439300 | 0.79 | ERN1 (0.40) | ERN1TTRALBMEN1KMT2A | |
| SCHEMBL3679283 | 0.79 | TTR (0.54) | TTRALBMEN1KMT2AVCAM1 | |
| SCHEMBL17323197 | 0.77 | ERN1 (0.41) | ERN1MEN1KMT2APIM1 | |
| SCHEMBL24190768 | 0.75 | ERN1 (0.60) | ERN1 | |
| SCHEMBL17348537 | 0.73 | FASN (0.35) | ERN1TTRALBMEN1KMT2A | |
| SCHEMBL6898133 | 0.73 | VCAM1 (0.40) | TTRALBMEN1KMT2AVCAM1 | |
| SCHEMBL7366982 | 0.73 | TTR (0.48) | TTRALBMEN1KMT2AVCAM1 | |
| SCHEMBL7195384 | 0.72 | RAD51 (0.40) | VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580379-B2 | Xanthine oxidase inhibitors and methods of use | BAYLOR COLLEGE OF MEDICINE (US) | 2017-02-28 | — | — | US | disclosed |
| WO-2015191635-A2 | XANTHINE OXIDASE INHIBITORS AND METHODS OF USE | BAYLOR COLLEGE OF MEDICINE (US) | 2015-12-17 | — | — | WO | disclosed |
| US-20150353471-A1 | XANTHINE OXIDASE INHIBITORS AND METHODS OF USE | BAYLOR COLLEGE OF MEDICINE | 2015-12-10 | — | — | US | disclosed |
| US-3941776-A | RACEMIZATION OF AMINOLACTAM COMPOUNDS | ALLIED CHEMICAL CORPORATION (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353471-A1 | XANTHINE OXIDASE INHIBITORS AND METHODS OF USE | XDH, PNPO, AOX1 | ERN1 1631/4885TTR 2345/4885ALB 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.